Get started
Author

Adnan Alsumali

Observed names: A Alsumali, A. Alsumali, Alsumali, Adnan
ORCID: 0000-0002-5139-3583
Observed ORCID: 0000-0002-5139-3583
OpenAlex ID: A5048853751
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
2022 · Hardik Goswami, Adnan Alsumali, et al. · PharmacoEconomics · 40
PDF
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
2021 · Adnan Alsumali, Laurence M Djatche, et al. · PharmacoEconomics · 32
PDF
Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
2021 · Adnan Alsumali, Dominik Lautsch, et al. · Advances in Therapy · 25
PDF
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States
2024 · Anna Watzker, Adnan Alsumali, et al. · PharmacoEconomics · 22
PDF
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH)
2023 · Vallerie McLaughlin, Adnan Alsumali, et al. · Advances in Therapy · 22
PDF
Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective
2020 · Adnan Alsumali, Roy F. Chemaly, et al. · Journal of Medical Virology · 20
Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong
2020 · Thomas Sau-Yan Chan, Sally Shuk-Yee Cheng, et al. · Journal of Medical Economics · 19
PDF
Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
2020 · Dominik Lautsch, Adnan Alsumali, et al. · Diabetes Therapy · 11
PDF
Validating the UK prospective diabetes study outcome model 2 using data of 94,946 Israeli patients with type 2 diabetes
2021 · Xiaohui Zhuo, Cheli Melzer Cohen, et al. · Journal of Diabetes and its Complications · 6
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
2020 · Elizabeth Wehler, Dominik Lautsch, et al. · PharmacoEconomics · 4
PDF
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model
2025 · Adnan Alsumali, Vallerie McLaughlin, et al. · Advances in Therapy · 2
PDF
Pdb45 the Budget Impact of Sitagliptin Versus Oral Semaglutide From a Us Payer Perspective
2020 · A. Alsumali, D. Lautsch, et al. · Value in Health · 2
Impact of Delaying Access to Sotatercept on Patients Living With Pulmonary Arterial Hypertension
2024 · V.V. Mclaughlin, A. Alsumali, et al. · 1
Loss of Productivity Among Commercially Insured Patients Treated for Pulmonary Arterial Hypertension
2024 · A. Watzker, C. Ferro, et al. · 1
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
2023 · Hardik Goswami, Adnan Alsumali, et al. · PharmacoEconomics · 1
PDF
PCV9 Budget IMPACT Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event in the United States
2021 · A. Alsumali, D. Lautsch, et al. · Value in Health · 1
PIN31 Budget-IMPACT Analysis of Letermovir for Preventing Cytomegalovirus in Adult Cytomegalovirus Seropositive Allogeneic Hematopoietic Cell Transplant Recipients in the United States
2021 · A. Alsumali, A. Raval, et al. · Value in Health · 1
A Systematic Assessment of Budget Impact Models for Medical Devices
2018 · R Basu, A Alsumali · Value in Health · 1
Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension
2026 · Adnan Alsumali, Vasco M. Pontinha, et al. · PharmacoEconomics
PDF
Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States
2026 · Anna Watzker, Christine Ferro, et al. · Journal of Medical Economics
Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States
2026 · Watzker, Anna, Ferro, Christine, et al. · Figshare
The Potential Impact of Sotatercept on Long-Term Disability in Commercially Insured Patients with Pulmonary Arterial Hypertension in the United States: An Exercise in Actuarial Modeling
2025 · Anna Watzker, Adnan Alsumali, et al. · Advances in Therapy
PDF
Acute Inpatient Utilization Among Medicaid Patients Treated for Pulmonary Arterial Hypertension
2025 · A. Watanabe, C. Ferrro, et al. · American Journal of Respiratory and Critical Care Medicine
Real-World Medication Cost Burden Among Patients Treated for Pulmonary Arterial Hypertension
2024 · A. Watzker, C. Ferro, et al.
Cost Differences Among Patients Diagnosed With Pulmonary Arterial Hypertension Based on Medicare Low-Income Subsidy Eligibility
2024 · A. Watzker, C. Ferro, et al.
Works count: 28
Citation count: 211
H-index: 8
I10-index: 8
Year
Topic
Type